Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aura Biosciences (AURA) Research & Development (2020 - 2026)

Aura Biosciences filings provide 7 years of Research & Development readings, the most recent being $28.0 million for Q1 2026.

  • Quarterly Research & Development rose 19.78% to $28.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $94.9 million through Mar 2026, up 19.25% year-over-year, with the annual reading at $90.3 million for FY2025, 23.19% up from the prior year.
  • Research & Development hit $28.0 million in Q1 2026 for Aura Biosciences, up from $21.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $28.0 million in Q1 2026 and bottomed at $8.3 million in Q1 2022.
  • Average Research & Development over 5 years is $17.6 million, with a median of $17.0 million recorded in 2024.
  • The largest annual shift saw Research & Development skyrocketed 97.75% in 2022 before it dropped 1.96% in 2025.
  • Aura Biosciences' Research & Development stood at $13.2 million in 2022, then surged by 54.12% to $20.3 million in 2023, then increased by 10.13% to $22.3 million in 2024, then dropped by 1.96% to $21.9 million in 2025, then rose by 27.69% to $28.0 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Research & Development are $28.0 million (Q1 2026), $21.9 million (Q4 2025), and $22.2 million (Q3 2025).